5PSQ-074 Activity of enzalutamide after abiraterone in castration-resistant prostate cancer

BACKGROUND: There is only limited information about the sequential use of abiraterone acetate (AA) and enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients. Patients who receive AA or ENZ as first-line therapy and subsequently become resistant have only a response r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Soto, A Alcalá, Moreno, R Gavira, Sánchez, JF Sierra, Pérez, A Varas, Pichardo, L Jiménez, Moreno, C Puivecino, Calvo, MT Gómez de Travecedo y
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 5: Patient safety and quality assurance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.428
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados